Figure 3.

Therapeutic approaches in multiple myeloma targeting the bone marrow microenvironment. Among these, five main types can be distinguished: (i) monoclonal antibodies targeting CD38 such as daratumumab and isatuximab, (ii) immunomodulatory substances such as thalidomide, lenalidomide, and pomalidomide, (iii) CAR T cells target mainly BCMA, other targets such as CD38, CD138, and SLAMF7 are being developed, (iv) bispecific antibodies bind mainly CD3 and BCMA, which are currently under clinical investigation, (v) antibody-drug conjugates, including the FDA-approved belantamab mafodotin along with MEDI2228 and HDP-101, which are still being tested. Created with BioRender.com (accessed on 30 June 2022).